blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2751095

EP2751095 - NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  02.09.2022
Database last updated on 13.11.2024
FormerThe patent has been granted
Status updated on  24.09.2021
FormerGrant of patent is intended
Status updated on  13.05.2021
FormerExamination is in progress
Status updated on  05.02.2021
FormerGrant of patent is intended
Status updated on  29.06.2020
FormerExamination is in progress
Status updated on  19.05.2020
FormerGrant of patent is intended
Status updated on  19.09.2019
FormerExamination is in progress
Status updated on  16.10.2018
FormerGrant of patent is intended
Status updated on  13.02.2018
FormerExamination is in progress
Status updated on  17.01.2018
FormerGrant of patent is intended
Status updated on  09.05.2017
FormerExamination is in progress
Status updated on  14.04.2017
FormerGrant of patent is intended
Status updated on  13.12.2016
FormerExamination is in progress
Status updated on  11.11.2016
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024  [2024/41]
Applicant(s)For all designated states
Sanford-Burnham Medical Research Institute
10901 North Torrey Pines Road
La Jolla, CA 92037 / US
[2021/43]
Former [2014/28]For all designated states
Sanford-Burnham Medical Research Institute
10901 North Torrey Pines Road
La Jolla, CA 92037 / US
Inventor(s)01 / HUTCHINSON, John Howard
3636 Nobel Drive
Suite 215
San Diego, California 92122 / US
02 / BLEICHER, Leo
3636 Nobel Drive
Suite 215
San Diego, California 92122 / US
03 / COSFORD, Nick
10901 North Torrey Pines Road
La Jolla, California 92037 / US
04 / ARDECKY, Robert John
10901 North Torrey Pines Road
La Jolla, California 92037 / US
05 / ZOU, Jiwen
10901 North Torrey Pines Road
La Jolla, California 92037 / US
 [2014/28]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2021/43]
Former [2014/28]Lawrence, John
Barker Brettell LLP
100 Hagley Road
Edgbaston
Birmingham
B16 8QQ / GB
Application number, filing date12827691.229.08.2012
[2021/43]
WO2012US52904
Priority number, dateUS201161528639P29.08.2011         Original published format: US 201161528639 P
[2014/28]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2013033246
Date:07.03.2013
Language:EN
[2013/10]
Type: A2 Application without search report 
No.:EP2751095
Date:09.07.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 07.03.2013 takes the place of the publication of the European patent application.
[2014/28]
Type: B1 Patent specification 
No.:EP2751095
Date:27.10.2021
Language:EN
[2021/43]
Search report(s)International search report - published on:KR02.05.2013
(Supplementary) European search report - dispatched on:EP06.03.2015
ClassificationIPC:C07D403/04, C07D409/14, C07D243/14, A61K31/5513, A61P25/00
[2014/28]
CPC:
C07D403/04 (EP,US); A61K31/551 (EP,US); A61K45/06 (EP,US);
A61P25/00 (EP); C07D243/12 (EP,US); C07D243/14 (EP,US);
C07D409/14 (EP,US); C07D417/04 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/28]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:NEUE BENZODIAZEPINONE ALS MODULATOREN DER METABOTROPEN GLUTAMATREZEPTORFUNKTIONEN UND NEUROLOGISCHE VERWENDUNGEN DAVON[2017/02]
English:NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF[2014/28]
French:NOUVEAUX BENZODIAZÉPINONES EN TANT QUE MODULATEURS DE FONCTIONS D'UN RÉCEPTEUR MÉTABOTROPIQUE DU GLUTAMATE, ET UTILISATIONS NEUROLOGIQUES DE CEUX-CI[2014/28]
Former [2014/28]NEUE BENZODIAZEPINONE ALS MODULATOREN DER METABOTROPEN GLUTAMATREZEPTORFUNKTIONEN UND NEUROLOGISCHE VERWENDUNGEN DAVON
Entry into regional phase28.02.2014National basic fee paid 
28.02.2014Search fee paid 
28.02.2014Designation fee(s) paid 
28.02.2014Examination fee paid 
Examination procedure28.02.2014Examination requested  [2014/28]
24.09.2015Amendment by applicant (claims and/or description)
21.01.2016Despatch of a communication from the examining division (Time limit: M06)
07.11.2016Reply to a communication from the examining division
14.12.2016Communication of intention to grant the patent
10.04.2017Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
10.05.2017Communication of intention to grant the patent
02.01.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
14.02.2018Communication of intention to grant the patent
08.10.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
20.09.2019Communication of intention to grant the patent
19.05.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
30.06.2020Communication of intention to grant the patent
01.12.2020Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
04.02.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
12.04.2021Cancellation of oral proceeding that was planned for 05.07.2021
14.05.2021Communication of intention to grant the patent
05.07.2021Date of oral proceedings (cancelled)
20.09.2021Fee for grant paid
20.09.2021Fee for publishing/printing paid
20.09.2021Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  21.01.2016
Opposition(s)28.07.2022No opposition filed within time limit [2022/40]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
04.02.2021Request for further processing filed
04.02.2021Full payment received (date of receipt of payment)
Request granted
15.02.2021Decision despatched
The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
19.05.2020Request for further processing filed
19.05.2020Full payment received (date of receipt of payment)
Request granted
02.06.2020Decision despatched
The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
08.10.2018Request for further processing filed
08.10.2018Full payment received (date of receipt of payment)
Request granted
16.09.2019Decision despatched
The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
02.01.2018Request for further processing filed
02.01.2018Full payment received (date of receipt of payment)
Request granted
22.01.2018Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
07.11.2016Request for further processing filed
07.11.2016Full payment received (date of receipt of payment)
Request granted
16.11.2016Decision despatched
Fees paidRenewal fee
27.08.2014Renewal fee patent year 03
27.08.2015Renewal fee patent year 04
29.08.2016Renewal fee patent year 05
28.08.2017Renewal fee patent year 06
28.02.2019Renewal fee patent year 07
27.08.2019Renewal fee patent year 08
27.08.2020Renewal fee patent year 09
27.08.2021Renewal fee patent year 10
Penalty fee
Additional fee for renewal fee
31.08.201807   M06   Fee paid on   28.02.2019
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.08.2012
AL27.10.2021
AT27.10.2021
CY27.10.2021
CZ27.10.2021
DK27.10.2021
EE27.10.2021
ES27.10.2021
FI27.10.2021
HR27.10.2021
IT27.10.2021
LT27.10.2021
LV27.10.2021
MC27.10.2021
MK27.10.2021
MT27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SI27.10.2021
SK27.10.2021
SM27.10.2021
TR27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
[2024/41]
Former [2024/29]HU29.08.2012
AL27.10.2021
AT27.10.2021
CY27.10.2021
CZ27.10.2021
DK27.10.2021
EE27.10.2021
ES27.10.2021
FI27.10.2021
HR27.10.2021
IT27.10.2021
LT27.10.2021
LV27.10.2021
MC27.10.2021
MK27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SI27.10.2021
SK27.10.2021
SM27.10.2021
TR27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2024/27]HU29.08.2012
AL27.10.2021
AT27.10.2021
CY27.10.2021
CZ27.10.2021
DK27.10.2021
EE27.10.2021
ES27.10.2021
FI27.10.2021
HR27.10.2021
IT27.10.2021
LT27.10.2021
LV27.10.2021
MC27.10.2021
MK27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SI27.10.2021
SK27.10.2021
SM27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2024/21]HU29.08.2012
AL27.10.2021
AT27.10.2021
CY27.10.2021
CZ27.10.2021
DK27.10.2021
EE27.10.2021
ES27.10.2021
FI27.10.2021
HR27.10.2021
IT27.10.2021
LT27.10.2021
LV27.10.2021
MC27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SI27.10.2021
SK27.10.2021
SM27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2024/18]HU29.08.2012
AL27.10.2021
AT27.10.2021
CZ27.10.2021
DK27.10.2021
EE27.10.2021
ES27.10.2021
FI27.10.2021
HR27.10.2021
IT27.10.2021
LT27.10.2021
LV27.10.2021
MC27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SI27.10.2021
SK27.10.2021
SM27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2023/27]AL27.10.2021
AT27.10.2021
CZ27.10.2021
DK27.10.2021
EE27.10.2021
ES27.10.2021
FI27.10.2021
HR27.10.2021
IT27.10.2021
LT27.10.2021
LV27.10.2021
MC27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SI27.10.2021
SK27.10.2021
SM27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2023/16]AL27.10.2021
AT27.10.2021
CZ27.10.2021
DK27.10.2021
EE27.10.2021
ES27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
MC27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SI27.10.2021
SK27.10.2021
SM27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2023/01]AL27.10.2021
AT27.10.2021
CZ27.10.2021
DK27.10.2021
EE27.10.2021
ES27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SI27.10.2021
SK27.10.2021
SM27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2022/49]AL27.10.2021
AT27.10.2021
CZ27.10.2021
DK27.10.2021
EE27.10.2021
ES27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SK27.10.2021
SM27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2022/35]AT27.10.2021
CZ27.10.2021
DK27.10.2021
EE27.10.2021
ES27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SK27.10.2021
SM27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2022/34]AT27.10.2021
EE27.10.2021
ES27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SM27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2022/33]AT27.10.2021
ES27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
NL27.10.2021
PL27.10.2021
RS27.10.2021
SE27.10.2021
SM27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2022/25]AT27.10.2021
ES27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
NL27.10.2021
PL27.10.2021
RS27.10.2021
SE27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2022/24]AT27.10.2021
ES27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
NL27.10.2021
PL27.10.2021
RS27.10.2021
SE27.10.2021
BG27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2022/23]AT27.10.2021
ES27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
PL27.10.2021
RS27.10.2021
BG27.01.2022
PT28.02.2022
Former [2022/22]AT27.10.2021
FI27.10.2021
LT27.10.2021
RS27.10.2021
BG27.01.2022
Former [2022/21]AT27.10.2021
RS27.10.2021
BG27.01.2022
Former [2022/19]BG27.01.2022
Documents cited:Search[I]WO0129012  (HOFFMANN LA ROCHE [CH]) [I] 1-12 * Compounds/formulas excluded by the specific combined definitions of present R4 and R8;; claims 1-12 * * abstract *;
 [I]WO02083652  (HOFFMANN LA ROCHE [CH]) [I] 1-12 * Compounds/formulas excluded by the specific combined definitions of present R4 and R8; page 18 - page 21; claims 1-20 ** abstract *;
 [I]WO03066623  (HOFFMANN LA ROCHE [CH]) [I] 1-12 * Compounds/formulas excluded by the specific combined definitions of present R4 and R8;; claims 1-29 * * abstract *;
 [I]EP2137167  (HOFFMANN LA ROCHE [CH]) [I] 1-12 * Compounds/formulas excluded by the specific combined definitions of present R4 and R8;; claims 1-18 * * the whole document *
by applicantEP2137167
 WO0129012
 WO03066623
 WO02083652
 US2010009983
 US2010216734
 US2008171750
 US2007015138
 US2005009742
 US2005009847
 US2005032702
 US2005031538
 US2005004046
 US2004254152
 US2004229291
 US2004185429
 US2007049576
 US2007208029
 US2007112017
 US2007270449
 US2008167291
 US2008103165
 EP0487155
    - MILLIGAN, DRUG DISCOV TODAY, (2006), vol. 11, no. 11-12, pages 541 - 549
    - ROMANO ET AL., J BIOL CHEM, (1996), vol. 271, no. 45, pages 28612 - 28616
    - GONZALEZ-MAESO ET AL., NATURE, (2008), vol. 452, no. 7183, pages 93 - 97
    - KIM ET AL., J. NEUROSCI., (2010), vol. 30, page 3870
    - CARACI ET AL., MOL PHARMACOL., (2011), vol. 79, page 618
    - PATIL ET AL., NATURE MED, (2007), vol. 13, page 1102
    - SAMADI ET AL., J. NEUROPATHOL. EXP. NEUROL, (2009), vol. 68, page 374
    - YOSHIMIZU ET AL., PSYCHOPHARMACOLOGY, (2006), vol. 186, pages 587 - 593
    - YOSHIMIZU ET AL., PSYCHOPHARMACOLOGY, (2006), vol. 186, pages 587 - 5930
    - BAPTISTA ET AL., J. NEUROSCI, (2004), vol. 33, page 4723
    - DHANYA ET AL., J. MED. CHEM, (2011), vol. 54, page 342
    - TSUNOKA ET AL., PROG. NEUROPSYCHOPHARMACOL BIOL PSYCHIATRY, (2010), vol. 34, page 639
    - KINON ET AL., J. CLIN PSYCHOPHARMACOL, (2011), vol. 31, page 349
    - KINON ET AL., J. CLIN. PSYCHOPHARMACOL., (2011), vol. 31, no. 3, pages 349 - 355
    - CARLTON ET AL., BRAIN RES, (2009), vol. 1248, page 86
    - ZHANG ET AL., BRAIN RES. BULLETIN, (2009), vol. 79, pages 219 - 223
    - NIKIFORUK ET AL., JPET, (2010), vol. 335, page 665
    - KARASAWA ET AL., BRAIN RES., (2005), vol. 1042, no. 1, pages 92 - 98
    - LI ET AL., SCIENCE, (2010), vol. 329, no. 5994, pages 959 - 964
    - KOIKE ET AL., NEUROPHARM., (2011), vol. 61, no. 8, pages 1419 - 1423
    - DWYER ET AL., INT. J. NEUROPSYCHOPHARMACOI., (2012), vol. 15, no. 4, pages 429 - 434
    - D'INOFRIO ET AL., J. NEUROCHEM, (2003), vol. 84, pages 1288 - 1295
    - ARCELLA ET AL., NEURO-ONCOLOGY, (2005), vol. 7, pages 236 - 245
    - PRICKETT ET AL., NATURE GENETICS, (2011), vol. 43, pages 1119 - 1126
    - CHATTOPADHYAY ET AL., ONCOLOGY REPORTS, (2009), vol. 21, pages 1135 - 1146
    - DWYER ET AL., INT. J. NEUROPSYCHOPHARMACOL., (2012), vol. 15, no. 4, pages 429 - 434
    - Remington's Pharmaceutical Sciences, MACK PUBLISHING COMPANY, (1985), page 1418
    - BEER ET AL., "DOV 216,303, a ''triple'' reuptake inhibitor: safety, tolerability, and pharmacokinetic profile", J CLIN PHARMACOL., (2004), vol. 44, no. 12, pages 1360 - 7
    - SKOLNICK ET AL., "Antidepressant-like actions of DOV 21,947: a ''triple'' reuptake inhibitor", EUR J PHARMACOL., (2003), vol. 461, no. 2-3, pages 99 - 104
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.